Citation Impact
Citing Papers
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
2011 Standout
Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer
2011 Standout
Pathology Without Crisis? The Strange Demise of the Anglo-Liberal Growth Model
2010
Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer
2003
Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma
2006
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study
2014
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF
2005
Gastric cancer
2016 Standout
Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)
2018
Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma
2003
Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres
2010 Standout
Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer
2001
ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology
2006 Standout
Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial
1999
Treatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or a cisplatin-based regimen
1998
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
2006 Standout
Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial
2010
A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer
2010
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
2014 Standout
Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial
2010
Irinotecan in the treatment of gastric cancer
2003
Natural products: An evolving role in future drug discovery
2011 Standout
Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial
2009
Phase II Trial of XELOX as First-Line Treatment for Patients with Advanced Gastric Cancer
2010
Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial
2010 Standout
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma
2004
Randomized Prospective Phase II Study to Compare the Combination Chemotherapy Regimen Epirubicin, Cisplatin, and 5-Fluorouracil With Epirubicin, Cisplatin, and Capecitabine in Patients With Advanced or Metastatic Gastric Cancer
2011
Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START)
2013
Covid-19 and the politics of sustainable energy transitions
2020
Esophageal Cancer
2003 Standout
Chemotherapy for advanced gastric cancer
2010
First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study
2007
A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer
2002
Chemotherapy for advanced gastric cancer
2005
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
2009
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
2015 Standout
Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer
2009
Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials
2006
Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine
2007 Standout
Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer
2007
Mind the gap: A survey of how cancer drug carriers are susceptible to the gap between research and practice
2013
Oesophageal carcinoma
2013 Standout
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma
2007
Guidelines for the management of oesophageal and gastric cancer
2011
A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction
2009
Gastric Small Cell Carcinoma Successfully Treated by Surgery and Postoperative Chemotherapy Consisting of Cisplatin and S-1: Report of a Case
2007 StandoutNobel
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
2012 Standout
A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction
2010
Gastric cancer
2020 Standout
Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer
2010
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer
2002
Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?
1998
Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study
2002
A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma
2008
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer
2012
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction
2008
The status of platinum anticancer drugs in the clinic and in clinical trials
2010 Standout
Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer
2014
Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype
2014
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
2008 Standout
Deciphering the Liquidity and Credit Crunch 2007–2008
2009 Standout
The British Regulatory State
2003 Standout
Asymmetric Growth and Institutions in an Interdependent World
2017 StandoutNobel
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
A randomized multi-center phase II trial of capecitabine (X) versus S-1 (S) as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer
2007
The EU needs to improve its external energy security
2022 Standout
Landscapes of care
2010 Standout
The side effects of platinum-based chemotherapy drugs: a review for chemists
2018 Standout
Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data
2006
S-1 plus oxaliplatin vs. S-1 as first-line treatment in patients with previously untreated advanced gastric cancer: a randomized phase II study
2013
Randomized Phase III Trial of Fluorouracil Alone Versus Fluorouracil Plus Cisplatin Versus Uracil and Tegafur Plus Mitomycin in Patients With Unresectable, Advanced Gastric Cancer: The Japan Clinical Oncology Group Study (JCOG9205)
2002
The Routledge Handbook of Political Ecology
2015 Standout
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
2006 Standout
Randomized Multicenter Phase II Trial of a Biweekly Regimen of Fluorouracil and Leucovorin (LV5FU2), LV5FU2 Plus Cisplatin, or LV5FU2 Plus Irinotecan in Patients With Previously Untreated Metastatic Gastric Cancer: A Fédération Francophone de Cancérologie Digestive Group Study—FFCD 9803
2004
A simple template for pitching research
2015 Standout
Wounded cities: Memory-work and a place-based ethics of care
2011 Standout
Privatised Keynesianism: An Unacknowledged Policy Regime
2009
Cultural-economy and cities
2007 Standout
Weekly Infusional High-Dose Fluorouracil (HD-FU), HD-FU Plus Folinic Acid (HD-FU/FA), or HD-FU/FA Plus Biweekly Cisplatin in Advanced Gastric Cancer: Randomized Phase II Trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie
2007
UK Economic Policy and the Global Financial Crisis: Paradigm Lost?*
2009
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Chemotherapy for advanced gastric cancer
2017 Standout
Disparities in Gastric Cancer Chemotherapy Between the East and West
2006
Power Resources and Employer-Centered Approaches in Explanations of Welfare States and Varieties of Capitalism: Protagonists, Consenters, and Antagonists
2006
Pandemic, War, and Global Energy Transitions
2022 Standout
Making sense of financialization
2014 Standout
Why do Similar Countries Choose Different Policies? Endogenous Comparative Advantage and Welfare Gains
2010
Phase II Study of Oxaliplatin, Fluorouracil, and Folinic Acid in Locally Advanced or Metastatic Gastric Cancer Patients
2002
The Paradox of Liberalization — Understanding Dualism and the Recovery of the G erman Political Economy
2012 Standout
The Influence of Emotional Intelligence on Performance in Competitive Sports: A Meta-Analytical Investigation
2018 Standout
Provisioning systems for a good life within planetary boundaries
2020 Standout
Variegated neoliberalization: geographies, modalities, pathways
2009 Standout
Final Results of a Randomized Phase III Trial of Sequential High-Dose Methotrexate, Fluorouracil, and Doxorubicin Versus Etoposide, Leucovorin, and Fluorouracil Versus Infusional Fluorouracil and Cisplatin in Advanced Gastric Cancer: A Trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group
2000
Institutional change in varieties of capitalism
2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer
2008
States, markets and an ethic of care
2005
The Business Firm as a Political Actor
2013 Standout
Docetaxel and Continuous-Infusion Fluorouracil Versus Epirubicin, Cisplatin, and Fluorouracil for Advanced Gastric Adenocarcinoma: A Randomized Phase II Study
2005
High Doses of 5-Fluorouracil and Epirubicin with or without Cisplatin in Advanced Gastric Cancer: A Randomized Study
1999
Management of Gastroesophageal Tumors
2007
Multivariate Prognostic Factor Analysis in Locally Advanced and Metastatic Esophago-Gastric Cancer—Pooled Analysis From Three Multicenter, Randomized, Controlled Trials Using Individual Patient Data
2004
Introduction to special issue on the material cultures of financialisation
2016
Wet Ontologies, Fluid Spaces: Giving Depth to Volume through Oceanic Thinking
2015 Standout
Common trajectories, variable paces, divergent outcomes? Models of European capitalism under conditions of complex economic interdependence
2004 Standout
The Matter of Carbon: Understanding the Materiality of tCO2e in Carbon Offsets
2011
Are we at risk of an uneven low-carbon transition? Assessing evidence from a mixed-method elite study
2021
Relational Places: The Surfed Wave as Assemblage and Convergence
2012
Paradigm man vs. the bricoleur: bricolage as an alternative vision of agency in ideational change
2011 Standout
Hydrogen in energy transition: A review
2021 Standout
Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer Research
2007
A revolution in finance?
2012
Financialisation and the Malaysian Political Economy
2010
Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer
2002
Quality of Life With Docetaxel Plus Cisplatin and Fluorouracil Compared With Cisplatin and Fluorouracil From a Phase III Trial for Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group
2007
Combination Chemotherapy with 5-Fluorouracil and Heptaplatin as First-line Treatment in Patients with Advanced Gastric Cancer
2004
Evaluation of the efficacy and toxicity of protocol cisplatin, 5-fluorouracil, leucovorin compared to protocol fluorouracil, doxorubicin and mitomycin C in locally advanced and metastatic gastric cancer
2012
Works of Matthew Watson being referenced
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
1997
Searching for the Kuhnian moment: the Black-Scholes-Merton formula and the evolution of modern finance theory
2007
Embedding the 'new economy' in Europe: a study in the institutional specificities of knowledge-based growth
2001
House Price Keynesianism and the Contradictions of the Modern Investor Subject
2010
Headlong into the Polanyian Dilemma: The Impact of Middle-Class Moral Panic on the British Government's Response to the Sub-prime Crisis
2009
Beyond Prospective Accountancy: Reassessing the Case for British Membership of the Single European Currency Comparatively
2006
The Political Economy of the Subprime Crisis: The Economics, Politics and Ethics of Response
2010
Constituting Monetary Conservatives via the ‘Savings Habit’: New Labour and the British Housing Market Bubble
2008
Trait emotional intelligence questionnaire full-form and short-form versions: Links with sport participation frequency and duration and type of sport practiced
2016
New directions in the international political economy of energy
2019
Endogenous Growth Theory: Explanation or Post Hoc Rationalisation for Policy?
2004
Performing Place in Nature Reserves
2003
The discourse of globalisation and the logic of no alternative: rendering the contingent necessary in the political economy of New Labour
2003
Ricardian Political Economy and the ‘Varieties of Capitalism’ Approach: Specialization, Trade and Comparative Institutional Advantage
2003
Planning for a Future of Asset-based Welfare? New Labour, Financialized Economic Agency and the Housing Market
2009
Introduction to the Political Economy of the Sub-prime Crisis in Britain: Constructing and Contesting Competence
2009
The institutional paradoxes of monetary orthodoxy: reflections on the political economy of central bank independence
2002